Nursing experience of comparison between Paclitaxel Liposomal plus cisplatin and Docetaxel combined with Cisplatin in the treatment of terminal non-small cell lung cancer

Objective To compare the effect of Paclitaxel Liposomal plus cisplatin(LP)and Docetaxel combined with Cisplatinum(DP)in the treatment of terminal non-small cell lung cancer (NSCLC).Methods A total of 60 patients were randomly divided into experimental group and control group with 30 patients in each group.Experimental group was treated with LP at a dose of 135 mg /m2 and the control group was given DP at a dose of 75 mg /m2,the cycle of two groups was 21 days.The curative effectiveness and adverse reaction were evaluated after 2 cycles.Results The difference was not significant in the clinical efficacy(P >0.05).The difference was statisti-cally significant since the incidence of peripheral neuritis in the experimental group was significantly lower than that in the control group(P <0.05).The difference was not statistically significant in nausea /vomiting,diarrhea,abdominal pain and alopecia (P >0.05).Conclusion The effects of LP and DP in the treatment of NSCLC are similar.However,LP treatment with better clinical ef-ficacy reduces the incidence rate of peripheral neuritis and decreases the occurrence of adverse reac-tion.